Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05527483 · ClinicalTrials.gov registry record
Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 32
- Enrollment target
NCT05527483 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 32 participants.
The verdict
NCT05527483 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen (\[Ga-68\]PSMA) for detection of bone metastasis in patients with prostate cancer. For imaging the investigators will use a FDA approved imaging technology, digital Positron Emission Tomography (PET/CT). The investigators would like to know if digital PET/CT using \[Ga-68\]PSMA provides accurate information about the extent of bone metastases. Therefore, the investigators will compare\[Ga-68\]PSMA PET/CT with Flourine-18 \[F-18\] Sodium Fluoride (NaF), which is a high resolution bone scan. \[F-18\]NaF is FDA approved and the reference standard for evaluating the presence of bone metastases.\[Ga-68\]PSMA is an investigational (experimental) drug that works by binding to Prostate Specific Membrane Antigen, which is overexpressed in prostate cancer. \[Ga-68\]PSMA is experimental because it is not approved by the Food and Drug Administration (FDA) at University Hospitals. However, FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application.
Interventions
- DIAGNOSTIC_TEST PET/CT
- DRUG [68Ga]PSMA
- DRUG Flourine-18 [F-18] Sodium Fluoride (NaF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2022-10-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05527483
The ClinicalTrials.gov registry entry for NCT05527483 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PET/CT is the first listed.
NCT05527483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05527483 about?
NCT05527483 is a clinical study titled "Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients". The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen (\[Ga-68\]PSMA) for detection of bone metastasis in patients with prostate cancer. For imaging the investigators will use a FDA approved imaging technology, di...
What is the current status of trial NCT05527483?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2022-04-21. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT05527483?
The interventions under investigation include: PET/CT (DIAGNOSTIC_TEST), [68Ga]PSMA (DRUG), Flourine-18 [F-18] Sodium Fluoride (NaF) (DRUG).
Who is sponsoring clinical trial NCT05527483?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.